daily oral glp-1 receptor agonist orforglipron for adults with obesity Pill Approved by FDA FDA approves Foundayo, an oral

No pancreatic safety concern following glucagon-like peptide-1 receptor agonist therapies: a pooled analysis of cardiovascular outcome trials

We compared GLP-1RAs with SGLT2 inhibitors and metformin and found that GLP-1RAs significantly reduced the incidence of major CVEs and mortality rate compared with metformin and second- or third-line glucose-lowering medications

Bariatric surgery and GLP-1 medications are taking the world by a storm right now not just because of their availability and effectiveness with helping with long-term obesity management and managing health crises related to weight

Public health systems in developed markets are establishing structured access pathways based on BMI thresholds combined with cardiovascular or metabolic comorbidities

, decreased compared to placebo

It is estimated that upwards of 30 million Americans will be on GLP-1 treatment in 2030 (an increase of 10 million from those on branded GLP-1s in 2026), making the growth of GLP-1s one of the key storylines to watch in the new year